D: 8 May 2013 Published: 16 Might 2013 References 1. Fabbri M, Croce CM, Calin GA: MicroRNAs. Cancer J 2008, 14:1. 2. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:21533. 3. Guo H, Ingolia NT, Weissman JS, Bartel DP: Mammalian microRNAs predominantly act to lower target mRNA levels. Nature 2010, 466:83540. four. Fort A, Borel C, Migliavacca E, Antonarakis SE, Fish RJ, Neerman-Arbez M: Regulation of fibrinogen production by microRNAs. Blood 2010, 116:2608615. 5. Teruel R, Perez-Sanchez C, Corral J, Herranz MT, Perez-Andreu V, Saiz E, Garcia-Barbera N, Martinez-Martinez I, Roldan V, Vicente V, L ez-Pedrera C, Martinez C: Identification of miRNAs as Potential Modulators of Tissue Aspect Expression in Sufferers with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. J Thromb Haemost 2011, 9:1985992. 6. Nagalla S, Shaw C, Kong X, Kondkar AA, Edelstein LC, Ma L, Chen J, McKnight GS, Lopez JA, Yang L, Jin Y, Bray MS, Leal SM, Dong JF, Bray PF: Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood 2011, 117:5189197. 7. Teruel R, Corral J, Perez-Andreu V, Martinez-Martinez I, Vicente V, Martinez C: Potential function of miRNAs in developmental haemostasis.Cuprizone Protocol PLoS A single 2011, 6:e17648. eight. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Castle V, Powers P: Development in the human coagulation system within the wholesome premature infant. Blood 1988, 72:1651657. 9. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P: Improvement from the human coagulation system inside the full-term infant. Blood 1987, 70:16572. 10. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L: Maturation on the hemostatic method throughout childhood.Trypsin Inhibitor, soybean supplier Blood 1992, 80:1998005. 11. Rau JC, Beaulieu LM, Huntington JA, Church FC: Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost 2007, 5(Suppl 1):10215. 12. Amrani DL, Mosesson MW, Koide T: Proof that chicken antithrombin III is really a developmentally regulated glycoprotein synthesized by hepatocytes. Biochim Biophys Acta 1985, 847:32434. 13. Niessen RW, Lamping RJ, Peters M, Lamers WH, Sturk A: Fetal and neonatal improvement of antithrombin III plasma activity and liver messenger RNA levels in sheep. Pediatr Res 1996, 39:68591. 14. Ishiguro K, Kojima T, Kadomatsu K, Nakayama Y, Takagi A, Suzuki M, Takeda N, Ito M, Yamamoto K, Matsushita T, Kusugami K, Muramatsu T, Saito H: Full antithrombin deficiency in mice results in embryonic lethality.PMID:25818744 J Clin Invest 2000, 106:87378. 15. Hagiwara S, Iwasaka H, Shingu C, Matsumoto S, Uchida T, Noguchi T: High-dose antithrombin III prevents heat stroke by attenuating systemic inflammation in rats. Inflamm Res 2010, 59:51118. 16. Larsson H, Akerud P, Nordling K, Raub-Segall E, Claesson-Welsh L, Bjork I: A novel anti-angiogenic form of antithrombin with retained proteinase binding capacity and heparin affinity. J Biol Chem 2001, 276:119962002.17. Guerrero JA, Teruel R, Martinez C, Arcas I, Martinez-Martinez I, de la MorenaBarrio ME, Vicente V, Corral J: Protective function of antithrombin in mouse models of liver injury. J Hepatol 2012, 57:98086. 18. Manco-Johnson MJ, Jacobson LJ, Hacker MR, Townsend SF, Murphy J, Hay W Jr: Development of coagulation regulatory proteins within the fetal and neonatal lamb. Pediatr Res 2002, 52:58088. 19. McCoy AJ, Pei XY, Skinner R, Abrahams JP, Carrell RW: Structure of beta-antithrombin as well as the impact of glycosylation on antithrombin’s heparin affinity a.
